VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 31, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has expanded its clinical trial of QBECO SSI in ulcerative colitis to include two new clinical trial sites in Edmonton, Alberta and Hamilton, Ontario, in addition to the existing site in Vancouver, British Columbia. Importantly, from a participant perspective, all participants in the study will receive QBECO treatment.

The clinical trial investigators are gastroenterologists Dr. Brian Bressler at the GI Research Institute in Vancouver, Dr. Richard Fedorak at the Division of Gastroenterology at the University of Alberta in Edmonton, and Dr. John Marshall at Hamilton Health Sciences at McMaster University in Hamilton.

Qu Biologics received a No Objection Letter (NOL) from Health Canada to proceed with the Phase 2 open-label, dose-ranging, proof-of-concept study to evaluate the safety, tolerability and efficacy of QBECO for the treatment of patients with moderate-to-severe ulcerative colitis. Concurrently, Qu Biologics continues to enroll patients in its double-blind, placebo-controlled study of QBECO for the treatment of moderate-to-severe Crohn's disease. Together, these trials are designed to evaluate the safety, tolerability and efficacy of Qu Biologics' proprietary SSI technology for the treatment of inflammatory bowel disease (IBD). QBECO SSI is derived from components of inactivated E. coli. Unlike current IBD treatments that work by suppressing the immune system, QBECO SSI is designed to restore the body's normal immune function in the gastrointestinal tract by stimulating an innate immune response and correcting a dysfunctional immune system.

To learn more about this clinical trial, visit www.quibd.com, email ulcerativecolitis@quibd.com, or call 1-855-209-9680.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSIs), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many illnesses, including cancer and other immune-related diseases. The company is currently recruiting participants for clinical trials in Crohn's disease, ulcerative colitis and recurrent non-small cell lung cancer to study SSI treatment.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com or www.quibd.com.

Qu Biologics Inc. cautions you that statements included in this release that are not a description of historical facts may contain forward-looking statements. These forward-looking statements are only predictions and may involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.